Cefepime neurotoxicity in the intensive care unit: a cause of severe, underappreciated encephalopathy

Jennifer E Fugate, Ejaaz A Kalimullah, Sara E Hocker, Sarah L Clark, Eelco F M Wijdicks, Alejandro A Rabinstein, Jennifer E Fugate, Ejaaz A Kalimullah, Sara E Hocker, Sarah L Clark, Eelco F M Wijdicks, Alejandro A Rabinstein

Abstract

Introduction: Cefepime, a broad spectrum antibiotic, is commonly prescribed in intensive care units (ICU) and may be an overlooked cause of neurologic symptoms such as encephalopathy, myoclonus, seizures, and coma. We aimed to characterize cefepime neurotoxicity in the ICU.

Methods: We performed a retrospective study of adult ICU patients treated with intravenous cefepime for at least 3 days between January 1, 2009 and December 31, 2011. The primary outcome was the development of cefepime neurotoxicity, with the likelihood of causality ascribed via a modified Delphi method.

Results: This study included 100 patients. The mean age was 65.8 years (± 12.7 years). The median daily average dose of cefepime was 2.5 (IQR 2.0 to 3.5) grams. The median treatment duration was 6 (IQR 4 to 10) days. Renal failure in any form was present in 84 patients. Chronic kidney disease affected 40 patients, and 77 had acute kidney injury. Cefepime neurotoxicity occurred in 15 patients. Of these, seven were considered definite cases, three probable, and five possible. Neurotoxic symptoms included impaired consciousness (n = 13), myoclonus (n = 11), disorientation (n = 6), and nonconvulsive status epilepticus (n = 1). The dose of cefepime was appropriately adjusted for renal clearance in 64 patients (75.3%) without cefepime neurotoxicity and four patients (28.6%) with neurotoxicity (P = 0.001). Chronic kidney disease was present in 30 patients (35.3%) without neurotoxicity and in 10 (66.7%) of those with neurotoxicity (P = 0.04).

Conclusions: Critically ill patients with chronic kidney disease are particularly susceptible to cefepime neurotoxicity. Myoclonus and impaired consciousness are the predominant clinical manifestations. Neurotoxic symptoms occur more often when the cefepime dose is not adjusted for renal function, but can still occur despite those modifications.

Figures

Figure 1
Figure 1
EEG findings in cefepime neurotoxicity. Electroencephalogram (longitudinal bipolar montage) of a patient receiving intravenous (IV) cefepime shows diffuse slowing of the background, atypical triphasic waves, and multifocal sharp waves.

References

    1. Barbhaiya RH, Knupp CA, Forgue ST, Matzke GR, Guay DR, Pittman KA. Pharmacokinetics of cefepime in subjects with renal insufficiency. Clin Pharmacol Ther. 1990;17:268–276. doi: 10.1038/clpt.1990.149.
    1. Smith NL, Freebairn RC, Park MA, Wallis SC, Roberts JA, Lipman J. Therapeutic drug monitoring when using cefepime in continuous renal replacement therapy: seizures associated with cefepime. Crit Care Resusc. 2012;17:312–315.
    1. Bresson J, Paugam-Burtz C, Josserand J, Bardin C, Mantz J, Pease S. Cefepime overdosage with neurotoxicity recovered by high-volume haemofiltration. J Antimicrob Chemother. 2008;17:849–850. doi: 10.1093/jac/dkn256.
    1. Capparelli FJ, Diaz MF, Hlavnika A, Wainsztein NA, Leiguarda R, Del Castillo ME. Cefepime- and cefixime-induced encephalopathy in a patient with normal renal function. Neurology. 1840;17:65.
    1. Chatellier D, Jourdain M, Mangalaboyi J, Ader F, Chopin C, Derambure P, Fourrier F. Cefepime-induced neurotoxicity: an underestimated complication of antibiotherapy in patients with acute renal failure. Intensive Care Med. 2002;17:214–217. doi: 10.1007/s00134-001-1170-9.
    1. Garces EO, de Azambuja MFA, da Silva D, Bragatti JA, Jacoby T, Thome FS. Renal failure is a risk factor for cefepime-induced encephalopathy. J Nephrol. 2008;17:526–534.
    1. Grill MF, Maganti R. Cephalosporin-induced neurotoxicity: clinical manifestations, potential pathogenic mechanisms, and the role of electroencephalographic monitoring. Ann Pharmacother. 2008;17:1843–1850. doi: 10.1345/aph.1L307.
    1. Jallon P, Fankhauser L, Du Pasquier R, Coeytaux A, Picard F, Hefft S, Assal F. Severe but reversible encephalopathy associated with cefepime. Neurophysiol Clin. 2000;17:383–386. doi: 10.1016/S0987-7053(00)00234-3.
    1. Lam S, Gomolin IH. Cefepime neurotoxicity: case report, pharmacokinetic considerations, and literature review. Pharmacotherapy. 2006;17:1169–1174. doi: 10.1592/phco.26.8.1169.
    1. Maganti R, Jolin D, Rishi D, Biswas A. Nonconvulsive status epilepticus due to cefepime in a patient with normal renal function. Epilepsy Behav. 2006;17:312–314. doi: 10.1016/j.yebeh.2005.09.010.
    1. Plensa E, Gallardo E, Ribera JM, Batlle M, Oriol A, Costa J. Nonconvulsive status epilepticus associated with cefepime in a patient undergoing autologous stem cell transplantation. Bone Marrow Transplant. 2004;17:119–120. doi: 10.1038/sj.bmt.1704314.
    1. Sonck J, Laureys G, Verbeelen D. The neurotoxicity and safety of treatment with cefepime in patients with renal failure. Nephrol Dial Transplant. 2008;17:966–970.
    1. Barr J, Fraser GL, Puntillo K, Ely EW, Gélinas C, Dasta JF, Davidson JE, Devlin JW, Kress JP, Joffe AM, Coursin DB, Herr DL, Tung A, Robinson BR, Fontaine DK, Ramsay MA, Riker RR, Sessler CN, Pun B, Skrobik Y, Jaeschke R. Clinical practice guidelines for the management of pain, agitation, and delirium in adult patients in the Intensive Care Unit. Crit Care Med. 2013;17:263–306.
    1. Girard TD, Pandharipande PP, Ely EW. Delirium in the intensive care unit. Crit Care Suppl. 2008;17:S3.
    1. Snavely SR, Hodges GR. The neurotoxicity of antibacterial agents. Ann Intern Med. 1984;17:92–104. doi: 10.7326/0003-4819-101-1-92.
    1. Hocker S, Rabinstein AA. A clinical and investigative approach to the patient with diminished responsiveness. Neurol Clin. 2011;17:739–747. doi: 10.1016/j.ncl.2011.07.003.
    1. FDA Drug Safety Communication. Cefepime and Risk of Seizure in Patients not Receiving Dosage Adjustments for Kidney Impairment. Available at: . Accessed April 26, 2013.
    1. Naeije G, Lorent S, Vincent JL, Legros B. Continuous epileptiform discharges in patients treated with cefepime or meropenem. Arch Neurol. 2011;17:1303–1307. doi: 10.1001/archneurol.2011.204.
    1. Gangireddy VG, Mitchell LC, Coleman T. Cefepime neurotoxicity despite renal adjusted dosing. Scand J Infect Dis. 2011;17:827–829. doi: 10.3109/00365548.2011.581308.
    1. Yadla M, Kishore CK, Sriramnaveen P, Reddy YS, Sainaresh VV, Bhuma V, Sivakumar V. Neurotoxicity due to cefepime in patients on maintenance hemodialysis. Saudi J Kidney Dis Transpl. 2011;17:1026–1027.
    1. Chapuis TM, Giannoni E, Majcherczyk PA, Chioléro R, Schaller MD, Berger MM, Bolay S, Décosterd LA, Bugnon D, Moreillon P. Prospective monitoring of cefepime in intensive care unit adult patients. Crit Care. 2010;17:R51. doi: 10.1186/cc8941.
    1. Durand-Maugard C, Lemaire-Hurtel AS, Gras-Champel V, Hary L, Maizel J, Prud'homme-Bernardy A, Andréjak C, Andréjak M. Blood and CSF monitoring of cefepime-induced neurotoxicity: nine case reports. J Antimicrob Chemother. 2012;17:1297–1299. doi: 10.1093/jac/dks012.

Source: PubMed

Sponsors en medewerkers

Medische omstandigheden

Geneesmiddelinterventies

3
Abonneren